Who is the Blood Pressure Service for?
The national programme aims to deliver a pathway within Primary Care for hypertension (high blood pressure) diagnoses, intervention, treatment, and ongoing monitoring.
There are three available protocols for a patient, the healthcare professional can enrol the patient on any of these protocols, but the default will be to start in Diagnosis and close monitoring protocol and move sequentially to the Medication titration protocol, and finally to Long term monitoring.
How will it work?
Diagnosis and close monitoring stage (Daily)
- Duration: 14 days (with the option to change to 7 days).
- Reporting: 14 days (with the option to change to 7 days).
- Readings: Every day at 8am and 5pm (with the option to change both these times).
Medication/Titration stage (Weekly)
- Duration: 3 months total.
- Reporting: Monthly – fixed.
- Readings: Tuesday and Friday at 8am and 5pm (with the option to change both days and times).
Long term monitoring stage (Monthly)
-
Duration: 10 years total.
-
Reporting: 6 months (with the option to change to 3 months or 12 months).
-
Readings: Twice a day on a Tuesday once a month at 8am and 5pm (with the option to change both day and times).
Objectives & Outcomes
-
Improves early detection and intervention around the management and support of hypertension.
-
Improve patient’s confidence with technology and self-management of condition.
-
Reduction in hypertension healthcare impacts (reduced risk of heart disease or stroke).
-
Underpins and supports the Scottish Government’s Programme for Government objectives.
-
Offers access to online support and information whilst also allowing the patient to be able to feed in important information on their condition from home and is appropriate to their needs.
-
Promotes self-management and a person-centred approach in effectively supporting and managing those citizens who have been diagnosed with hypertension.
Explore our National Blood Pressure patient guidance and further information.
If you are a healthcare professional and need further information, please explore our clinical resources on TURAS here.
